Blue Water Life Science Advisors LP Increases Stock Position in Personalis, Inc. (NASDAQ:PSNL)

Blue Water Life Science Advisors LP lifted its stake in shares of Personalis, Inc. (NASDAQ:PSNL - Free Report) by 13.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,132,900 shares of the company's stock after buying an additional 132,900 shares during the quarter. Personalis comprises 5.8% of Blue Water Life Science Advisors LP's portfolio, making the stock its 6th largest position. Blue Water Life Science Advisors LP owned approximately 1.60% of Personalis worth $6,548,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of PSNL. Jane Street Group LLC increased its stake in shares of Personalis by 154.3% in the 3rd quarter. Jane Street Group LLC now owns 164,281 shares of the company's stock worth $884,000 after acquiring an additional 99,671 shares in the last quarter. abrdn plc purchased a new stake in Personalis in the fourth quarter worth about $1,722,000. Barclays PLC increased its stake in shares of Personalis by 45.4% during the third quarter. Barclays PLC now owns 65,468 shares of the company's stock valued at $352,000 after purchasing an additional 20,444 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Personalis during the fourth quarter valued at approximately $64,000. Finally, State Street Corp boosted its position in shares of Personalis by 34.5% in the 3rd quarter. State Street Corp now owns 175,142 shares of the company's stock worth $942,000 after purchasing an additional 44,900 shares in the last quarter. 61.91% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have commented on PSNL. HC Wainwright reissued a "buy" rating and issued a $8.00 target price on shares of Personalis in a research note on Friday, February 28th. Lake Street Capital lifted their target price on shares of Personalis from $7.00 to $9.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. Needham & Company LLC reiterated a "buy" rating and set a $7.00 price target on shares of Personalis in a report on Thursday, April 10th. Finally, Craig Hallum assumed coverage on shares of Personalis in a report on Monday, March 17th. They issued a "buy" rating and a $8.00 price objective for the company. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Personalis currently has an average rating of "Buy" and a consensus price target of $7.80.

Personalis Stock Performance

Shares of PSNL stock traded up $0.21 on Wednesday, reaching $3.62. The stock had a trading volume of 605,269 shares, compared to its average volume of 965,189. The company has a 50 day simple moving average of $3.84 and a 200 day simple moving average of $4.52. The stock has a market cap of $319.67 million, a P/E ratio of -2.15 and a beta of 1.89. Personalis, Inc. has a 1 year low of $1.14 and a 1 year high of $7.20.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.32) by $0.09. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. The company had revenue of $16.80 million for the quarter, compared to the consensus estimate of $15.48 million. On average, equities research analysts anticipate that Personalis, Inc. will post -1.4 earnings per share for the current fiscal year.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.